fluorouracil and Neoplasms, Cystic, Mucinous, and Serous studies

fluorouracil and Neoplasms, Cystic, Mucinous, and Serous

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.

Research Excerpts

Excerpt	Relevance	Reference
"Most patients with pancreatic cancer remain asymptomatic until the disease reaches an advanced stage."	2.53	Pancreatic cancer. ( Itoi, T; Kamisawa, T; Takaori, K; Wood, LD, 2016)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors	Studies
Kamisawa, T	1
Wood, LD	1
Itoi, T	1
Takaori, K	1

Authors

Studies

Kamisawa, T

Wood, LD

Itoi, T

Takaori, K

Clinical Trials (5)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer[NCT04743479]		5,000 participants (Anticipated)	Observational	2020-12-01	Recruiting
Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study[NCT04677192]	Phase 2	50 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial[NCT04025840]	Phase 4	260 participants (Anticipated)	Interventional	2019-09-11	Recruiting
Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341]	Phase 3	306 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Shared Decision-making: Investigating the Potential of an Interactive, Web-Based, Information Tool for People With Advanced Pancreatic Cancer[NCT03632850]		34 participants (Actual)	Observational	2019-02-19	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer[NCT04743479]

5,000 participants (Anticipated)

Observational

2020-12-01

Recruiting

Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study[NCT04677192]

Phase 2

50 participants (Anticipated)

Interventional

2021-01-31

Not yet recruiting

Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial[NCT04025840]

Phase 4

260 participants (Anticipated)

Interventional

2019-09-11

Recruiting

Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341]

Phase 3

306 participants (Anticipated)

Interventional

2023-05-01

Recruiting

Shared Decision-making: Investigating the Potential of an Interactive, Web-Based, Information Tool for People With Advanced Pancreatic Cancer[NCT03632850]

34 participants (Actual)

Observational

2019-02-19

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for fluorouracil and Neoplasms, Cystic, Mucinous, and Serous

Article	Year
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr	2016

Article

Year

fluorouracil and Neoplasms, Cystic, Mucinous, and Serous

Research Excerpts

Research

Studies (1)

Authors

Clinical Trials (5)

Trial Overview

Reviews